Ascendis Pharma A/S (ASND) Cash Flow Statement

This shift suggests the company's core operations are now generating cash, moving beyond the phase where non-cash charges and working capital swings dominated the cash flow statement. The positive conversion in Q2 2026, alongside the massive net income figure, indicates the business model is beginning to translate accounting profits into tangible cash, a critical milestone for a scaling biotech.

This inflection appears directly tied to the commercial ramp of SKYTROFA and the initial YORVIPATH launch, which have driven revenue growth to 90.2% TTM. The sustainability of this high FCF margin is questionable, as it likely reflects favorable working capital dynamics from initial inventory stocking and milestone payments, rather than a steady-state operational profile.

These large, erratic swings suggest the cash flow profile is heavily influenced by the timing of receivables from specialty pharmacies and inventory build-up ahead of product launches. Investors should monitor whether these working capital benefits normalize as the commercial ramp matures, as they currently mask the underlying cash generation from core sales.

The initiation of buybacks, despite the company still being in a net loss position on a trailing basis, suggests management's confidence in the sustainability of the new cash flow trajectory. However, the scale of repurchases relative to the still-negative cumulative earnings warrants scrutiny, as it may prioritize shareholder returns over bolstering the balance sheet for future pipeline investments.